Skip to content
Study details
Enrolling now

Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer

Cedars-Sinai Medical Center
NCT IDNCT05086250ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

20

Study length

about 4.2 years

Ages

18+

Locations

1 site in CA

What this study is about

This trial is testing whether oral ketamine or a placebo can help reduce anxiety in people with pancreatic cancer. The goal is to see if it's possible to enroll enough patients and have them follow the treatment plan. Researchers will also look at safety, tolerability, and how ketamine/placebo affects anxiety symptoms and other health measures.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Ketamine
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)

Endpoints

Secondary: To investigate the safety of oral ketamine in patients with pancreatic cancer and anxiety, which will be assessed by the number of adverse events related to study treatment per CTCAE v.5., To investigate the tolerability of oral ketamine in patients with pancreatic cancer and anxiety, which will be measured by patient-reported Ketamine Adverse Symptom Checklist and Impact scores.

Body systems

Psychiatry / Mental Health, Oncology